ReviewCureus2020
Potential Protein Biomarkers for Preeclampsia.
Review in Cureus, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- The diagnostic potential of oxidative stress biomarkers for preeclampsia: systematic review and meta-analysis.Biology of sex differences · 2022Pooled it
- Therapeutic Interventions for Preeclampsia: Integrating Placental and Maternal Perspectives.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026Review
- Novel biomarkers for preeclampsia: Promises and pitfalls.Current opinion in obstetrics & gynecology · 2025Review
- Correlation of changes in circulating levels of hypoxia-induced factor-1α, erythropoietin, and cell-free fetal hemoglobin with feto-maternal pregnancy outcomes.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2025Article
- Single-cell RNA-seq reveals developmental deficiencies in both the placentation and the decidualization in women with late-onset preeclampsia.Frontiers in immunology · 2023Article
- Machine learning and bioinformatics framework integration reveal potential characteristic genes related to immune cell infiltration in preeclampsia.Frontiers in physiology · 2023Article
- Role of CA-125 Level as a Marker in the Management of Severe Pre-Eclampsia.Healthcare (Basel, Switzerland) · 2022Article
- Robust identification of temporal biomarkers in longitudinal omics studies.Bioinformatics (Oxford, England) · 2022Article
- COVID-19 and Preeclampsia: Overlapping Features in Pregnancy.Rambam Maimonides medical journal · 2022Review
- Integrated Learning: Screening Optimal Biomarkers for Identifying Preeclampsia in Placental mRNA Samples.Computational and mathematical methods in medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To date, the etiology of preeclampsia (PE) has not been clarified and the specific treatment is lacking; hence, early prediction and prevention are very important. Thus, a large number of biomarkers that may be associated with PE have been identified based on proteomics to provide a reference for the prediction of PE and for the understanding of the pathological mechanisms of this disease. This article briefly summarizes the application of proteomics in PE and the potential protein biomarkers to provide a reference for other researchers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.